Welcome to our dedicated page for Arcus Bioscience news (Ticker: RCUS), a resource for investors and traders seeking the latest updates and insights on Arcus Bioscience stock.
Arcus Biosciences, Inc. (NYSE: RCUS) generates frequent news as a clinical-stage, global biopharmaceutical company advancing investigational therapies for cancer, inflammatory diseases and autoimmune diseases. News about Arcus often centers on clinical trial updates for its lead programs, collaboration developments and corporate financing activities that support its pipeline.
Key oncology news items include data readouts and study milestones for casdatifan, a small-molecule HIF‑2α inhibitor being developed for clear cell renal cell carcinoma (ccRCC). Investors can follow announcements from the ARC‑20 Phase 1/1b study in late-line and early-line ccRCC, the global Phase 3 PEAK‑1 trial in immunotherapy-experienced metastatic ccRCC, and the eVOLVE‑RCC02 Phase 1b/3 study that combines casdatifan with volrustomig in first-line metastatic ccRCC. Updates often highlight progression-free survival, response rates, safety findings and the design of new cohorts or registrational strategies.
Arcus news also covers its broader oncology portfolio, including quemliclustat, a CD73 inhibitor in the PRISM‑1 Phase 3 trial for first-line metastatic pancreatic ductal adenocarcinoma, and the domvanalimab plus zimberelimab combinations in gastrointestinal and lung cancers. Coverage has included positive survival and response data from the Phase 2 EDGE‑Gastric study, as well as the later decision to discontinue the Phase 3 STAR‑221 and EDGE‑Gastric studies after an interim analysis showed no overall survival benefit over standard therapy.
On the inflammation and immunology side, Arcus issues updates on its emerging small-molecule programs targeting MRGPRX2, TNF, CCR6 and CD40L, and an anti‑CD89 antibody program. News may describe preclinical progress, selection of development candidates and plans to enter the clinic in indications such as atopic dermatitis, chronic spontaneous urticaria, rheumatoid arthritis, psoriasis, inflammatory bowel disease, multiple sclerosis and systemic lupus erythematosus.
Corporate and financial news for RCUS includes public equity offerings, amendments to loan facilities, participation in major healthcare and investor conferences, and guidance on cash runway. Readers can use this news page to follow how clinical data, partnership decisions with Gilead Sciences and Taiho Pharmaceutical, and capital-raising activities shape Arcus’s development priorities over time.
Arcus Biosciences (NYSE:RCUS) announced that its Compensation Committee granted inducement equity awards to two new employees on October 9, 2025. The awards include options to purchase a total of 60,300 shares at an exercise price of $15.05 (closing price on October 8, 2025) and restricted stock units to acquire 30,150 shares. The grants were made under the company’s 2020 Inducement Plan using the NYSE "inducement exception" (Rule 303A.08).
The announcement discloses award totals, per‑share exercise price, plan authority, and the date used for pricing.
Arcus Biosciences (NYSE:RCUS) reported Phase 1/1b casdatifan monotherapy data in late-line metastatic clear cell RCC showing a 100mg QD confirmed ORR 35% and pooled confirmed ORR 31% (n=121). Pooled median PFS was 12.2 months with an 18-month PFS of 43%. In the 100mg QD cohort, median PFS was not estimable at ~12.4 months median follow-up. Safety signals included grade ≥3 anemia (pooled 41%) and hypoxia (pooled 11%); treatment discontinuations were ~9%.
Arcus also disclosed five preclinical inflammation and immunology programs with a first clinical study expected in 2026. A webcast is available today at 7:00 AM PT / 10:00 AM ET.
Arcus Biosciences (NYSE:RCUS), a clinical-stage biopharmaceutical company, has granted equity-based compensation to two new employees. The awards include options to purchase 9,750 shares at an exercise price of $12.39 per share and restricted stock units (RSUs) for 4,900 shares. The grants were made under the company's 2020 Inducement Plan, approved under NYSE's inducement exception Rule 303A.08.
Arcus Biosciences (NYSE:RCUS), a clinical-stage biopharmaceutical company, has granted equity awards to three new employees. The compensation package includes options to purchase 19,300 shares at $12.19 per share and restricted stock units for 9,700 shares.
These equity awards were granted under the Company's 2020 Inducement Plan, which was established in January 2020 under the NYSE Listed Company Manual Rule 303A.08's "inducement exception".
Arcus Biosciences (NYSE:RCUS) will host an Investor Event on October 6, 2025, at 10:00 AM ET in New York City, offering both in-person and virtual attendance options. The event will showcase new data from the Phase 1b ARC-20 trial of their HIF-2a inhibitor casdatifan in clear cell renal cell carcinoma (ccRCC).
The presentation will feature management team members and key opinion leaders discussing HIF-2a biology and ccRCC treatment. Additionally, Arcus will present its research in autoimmune and inflammatory diseases, with planned new IND filings in 2026 and 2027.
Arcus Biosciences (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on cancer therapies, has announced its participation in three major investor conferences in September 2025:
- Citi's 2025 Biotech Back to School Conference on September 3rd in Boston at 11:15 a.m. ET
- H.C. Wainwright Global Investment Conference on September 9th in New York at 8:00 a.m. ET
- Morgan Stanley Global Healthcare Conference on September 10th in New York at 8:30 a.m. ET
All events will feature fireside chats and one-on-one meetings, with live webcasts available on the company's website.
Arcus Biosciences (NYSE:RCUS) reported Q2 2025 financial results and pipeline updates, highlighting significant progress in its oncology portfolio. The company ended the quarter with $927 million in cash, positioning it well for pipeline advancement. Key developments include the initiation of PEAK-1, a Phase 3 study of casdatifan + cabozantinib in RCC, and eVOLVE-RCC02, a Phase 1b/3 study with AstraZeneca.
Financial highlights include revenues of $160 million (up from $39M in Q2 2024), R&D expenses of $139 million, and break-even net income. The revenue increase was primarily driven by a $143 million cumulative catch-up related to etrumadenant program changes.
Clinical progress includes promising data from ARC-20 study showing 46% confirmed response rate in RCC patients, with additional data readouts expected in fall 2025 and 2026. The company anticipates R&D expenses to decline from Q4 2025 as domvanalimab Phase 3 costs decrease.
Arcus Biosciences (NYSE:RCUS), a clinical-stage biopharmaceutical company, has granted equity-based compensation to a new employee. The package includes options to purchase 4,200 shares at an exercise price of $9.75 per share and restricted stock units (RSUs) for 2,100 shares. The grants were made under the company's 2020 Inducement Plan, approved under NYSE Rule 303A.08's inducement exception.
Arcus Biosciences (NYSE:RCUS) announced that its investigational CD73 inhibitor, quemliclustat, received orphan drug designation from the FDA for pancreatic cancer treatment. The designation provides benefits including tax credits, user fee exemptions, and potential 7-year market exclusivity upon approval.
Phase 1 ARC-8 study results showed promising median overall survival of 15.7 months with quemliclustat-based regimens, surpassing historical chemotherapy benchmarks. The company's Phase 3 PRISM-1 trial, evaluating quemliclustat plus chemotherapy in 610 first-line metastatic pancreatic cancer patients, is expected to complete enrollment by end of 2025.
Arcus Biosciences (NYSE:RCUS), a clinical-stage biopharmaceutical company, has granted equity-based compensation to six new employees. The awards include 54,800 stock options at an exercise price of $8.50 per share and 27,550 restricted stock units (RSUs). These equity grants were made under the company's 2020 Inducement Plan, approved under NYSE Rule 303A.08's inducement exception.
FAQ
What is the current stock price of Arcus Bioscience (RCUS)?
What is the market cap of Arcus Bioscience (RCUS)?
